US › Healthcare

Arcturus Therapeutics Holdings Inc (ARCT)

US · Healthcare · Biotechnology

$16.93+8.53%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$3.0M

Revenue YoY

-87.9%

Net profit

$-23.8M

EPS

$-0.84

EPS estimate

$-1.07

Net margin

-803.8%

EPS came in at -0.84 against a street estimate of -1.07 — a beat of 21.5%.

Key statistics

Market cap

$415.0M

Forward P/E

2.5

P/B

2.31

Book value

$6.04

EPS (TTM)

$-3.33

52-week high

$24.17

52-week low

$5.50

50-day MA

$9.24

200-day MA

$7.89

Beta

2.48

Analyst view

Analysts rate Arcturus Therapeutics Holdings Inc a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $22.30.

Shareholding

Insiders

7.99%

Institutions

83.14%

Largest institutional holders

Fund	Stake
Federated Hermes Inc	11.62%
ARK Investment Management LLC	9.74%
BlackRock Inc	9.19%
Amova Asset Management Americas, Inc	8.05%
Sumitomo Mitsui Trust Group Inc	6.91%
Vanguard Capital Management, LLC	3.89%
Two Sigma Investments LLC	3.81%
Vanguard Portfolio Management, LLC	3.44%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Arcturus Therapeutics Holdings Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.